ERBB2 and breast cancer: With advanced research on molecular biology, the development of precision medicine, and the emergence of new antibody–drug conjugates (ADCs), HER2‐low breast cancer (characterized by IHC scores of 1+ or 2+ with negative fluorescence in situ hybridization) has been recognized to possess unique molecular features, holding promise as a new treatment subtype.